46
Participants
Start Date
June 30, 2006
Primary Completion Date
September 30, 2008
Study Completion Date
December 31, 2008
ATN-224 + bortezomib
ATN-224 and bortezomib dose to be determined in Phase I portion of study
SUNY Downstate, Brooklyn
Roswell Park Cancer Institute, Buffalo
Center for Cancer and Blood Disorders, Bethesda
Florida Cancer Specialists, Fort Myers
Billings Clinic, Billings
Mary Crowley Medical Research Center, Dallas
Tyler Cancer Center, Tyler
Institute for Myeloma and Bone Cancer Research, West Hollywood
Hematolgy-Oncology Medical Group of Fresno, Inc., Fresno
The Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Attenuon
INDUSTRY